Loading clinical trials...
Loading clinical trials...
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
KT-621
Placebo
Locations
61
United States
Kymera Investigative Site
Birmingham, Alabama, United States
Kymera Investigative Site
North Little Rock, Arkansas, United States
Kymera Investigative Site
Freemont, California, United States
Kymera Investigative Site
Los Angeles, California, United States
Kymera Investigative Site
Los Angeles, California, United States
Kymera Investigative Site
Santa Monica, California, United States
Start Date
November 24, 2025
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2028
Last Updated
April 23, 2026
NCT06116526
NCT06461897
NCT07262983
NCT06389136
NCT06342713
NCT07223697
Lead Sponsor
Kymera Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions